Estrogen therapy for brain gray matter atrophy and associated disability
AssigneeThe Regents of the University of California
InventorRhonda R. Voskuhl
Life of this patent
Estimating the term…
Abstract
Provided are methods for slowing, halting, and reversing gray matter atrophy and progression of disability in certain neurodegenerative diseases, including multiple sclerosis, using estrogen, alone or in combination with another agent.
Claims39
A method of (a) slowing, reversing, or halting gray matter atrophy;
- (b) slowing, reversing, or halting the progression of disability;
- (c) slowing, reversing, or halting the progression of memory loss;
- or (d) slowing, reversing, or halting the progression of a learning disability in a neurodegenerative disease patient, comprising administering to the patient an estrogen.
2-6. (canceled)
8-12. (canceled)
14-15. (canceled)
17-20. (canceled)
22-37. (canceled)
39-42. (canceled)
(canceled)
47-48. (canceled)
A method of treating a neurodegenerative disease, comprising
- administering to a subject in need thereof a treatment regimen;
- assessing a change in total brain gray matter volume of the subject over a period of time;
- and
- changing the treatment regimen if the total brain gray matter volume decreases by at least about 0.3 percent between a first assessment and a second assessment about 6 months after the first assessment, by at least about 0.6 percent between a first assessment and a second assessment about one year after the first assessment, or by at least about 1.0 percent between a first assessment and a second assessment about two years after the first assessment.
50-52. (canceled)
54-62. (canceled)
(canceled)
66-67. (canceled)
69-72. (canceled)
74-89. (canceled)
91-97. (canceled)
99-101. (canceled)
103-108. (canceled)
110-116. (canceled)
A method of treating a neurodegenerative disease in a patient who is non-responsive to treatment with a multiple sclerosis therapy, comprising administering to the patient an effective amount of an estrogen, wherein the patient is classified as non-responsive based on a substantial loss of brain gray matter volume or a substantial memory loss during treatment with the first treatment agent.
118-154. (canceled)
Dependencies are inferred from the claim text.